A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs NGM 313 (Primary)
- Indications Obesity
- Focus First in man; Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2016 Data from the trial are expected in 2017, according to an NGM Biopharmaceuticals media release.
- 17 Mar 2016 New trial record